A Study on the Treatment Strategy of NVG Secondary to PDR
NCT05156021
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
39
Enrollment
OTHER
Sponsor class
Conditions
Neovascular Glaucoma
Proliferative Diabetic Retinopathy
Interventions
DRUG:
anti-VEGF
Sponsor
Ruijin Hospital